ACAD · XBRL financial data

Acadia Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ACAD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	442	484	517	726	—	—
Revenue from contracts with customers	442	484	517	726	958	1,072
Cost of goods and services sold	10	11	10	42	82	89
Gross profit	432	473	507	685	—	—
Research and development	319	239	362	352	303	329
Selling, general and administrative	389	396	369	407	488	549
Operating income (loss)	(287)	(170)	(224)	(73)	231	105
Other income (expense)	(1)	(2)	4	5	2	2
Income tax expense (benefit)	1	0	3	10	32	(252)
Net income (loss)	(282)	(168)	(216)	(61)	226	391
Earnings per share, basic USD per share	(1.79)	(1.05)	(1.34)	(0.37)	1.37	2.32
Earnings per share, diluted USD per share	(1.79)	(1.05)	(1.34)	(0.37)	1.36	2.30
Weighted average shares, basic millions of shares	0	0	0	0	166	168
Weighted average shares, diluted millions of shares	0	0	0	0	166	170

Fiscal years (ACAD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	326	147	115	189	320	178
Marketable securities	306	373	302	250	436	642
Accounts receivable	48	64	62	98	99	121
Inventory	10	14	12	40	92	111
Prepaid and other current assets	—	—	—	—	—	60
Total current assets	718	618	508	616	938	1,062
Property and equipment, net	9	8	6	5	4	8
Right-of-use asset	47	58	56	52	47	47
Total assets	783	700	588	749	1,188	1,564
Accounts payable	8	7	13	18	16	11
Accrued liabilities	97	89	113	237	379	266
Total current liabilities	106	96	126	254	395	277
Lease liability, non-current	44	56	53	48	42	41
Total liabilities	156	159	187	317	455	337
Accumulated deficit	(1,986)	(2,154)	(2,370)	(2,431)	(2,204)	(1,813)
Total stockholders' equity	627	541	400	432	733	1,227
Total liabilities and equity	783	700	588	749	1,188	1,564
Common shares outstanding (cover page) millions of shares	160	161	162	165	167	170

Fiscal years (ACAD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(282)	(168)	(216)	(61)	226	391
Stock-based compensation	84	64	68	66	67	52
Net cash from operating activities	(136)	(126)	(114)	17	158	110
Purchases of property and equipment	8	1	0	0	1	5
Net cash from investing activities	193	(71)	73	32	(31)	(303)
Proceeds from issuing common stock	81	18	8	25	7	50
Net cash from financing activities	81	18	8	25	7	50
Net change in cash	137	(179)	(33)	74	134	(143)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	151	not reported	not reported	799.8M	—	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203	48	not reported	139.3M	—	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.